Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy.

Kumar P, Barua CC, Sulakhiya K, Sharma RK.

Front Pharmacol. 2017 Apr 4;8:132. doi: 10.3389/fphar.2017.00132. eCollection 2017.

2.

Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis.

Bandera Merchan B, Tinahones FJ, Macías-González M.

PPAR Res. 2016;2016:2308249. doi: 10.1155/2016/2308249. Epub 2016 Aug 8. Review.

3.

Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Irazabal MV, Torres VE.

Curr Hypertens Rev. 2013 Feb;9(1):44-59. Review.

4.

PPARγ agonists target aromatase via both PGE2 and BRCA1.

Margalit O, Wang D, Dubois RN.

Cancer Prev Res (Phila). 2012 Oct;5(10):1169-72. doi: 10.1158/1940-6207.CAPR-12-0365.

5.

The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells.

Bolden A, Bernard L, Jones D, Akinyeke T, Stewart LV.

PPAR Res. 2012;2012:929052. doi: 10.1155/2012/929052. Epub 2012 Feb 20.

6.

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Peters JM, Shah YM, Gonzalez FJ.

Nat Rev Cancer. 2012 Feb 9;12(3):181-95. doi: 10.1038/nrc3214. Review.

7.

Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells.

Lee SH, Richardson RL, Dashwood RH, Baek SJ.

J Nutr Biochem. 2012 Jun;23(6):646-55. doi: 10.1016/j.jnutbio.2011.03.009. Epub 2011 Jul 20.

9.

The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.

Moss PE, Lyles BE, Stewart LV.

Exp Cell Res. 2010 Dec 10;316(20):3478-88. doi: 10.1016/j.yexcr.2010.09.015. Epub 2010 Oct 13.

10.

Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.

Wang P, Dharmaraj N, Brayman MJ, Carson DD.

Mol Endocrinol. 2010 Jul;24(7):1368-79. doi: 10.1210/me.2009-0221. Epub 2010 May 19.

11.

MCC-555-induced NAG-1 expression is mediated in part by KLF4.

Cekanova M, Lee SH, McEntee MF, Baek SJ.

Eur J Pharmacol. 2010 Jul 10;637(1-3):30-7. doi: 10.1016/j.ejphar.2010.03.055. Epub 2010 Apr 10.

13.

Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification.

Yin Y, Yuan H, Zeng X, Kopelovich L, Glazer RI.

Cancer Res. 2009 Jan 15;69(2):687-94. doi: 10.1158/0008-5472.CAN-08-2446.

14.

The UPS: a promising target for breast cancer treatment.

Sato K, Rajendra E, Ohta T.

BMC Biochem. 2008 Oct 21;9 Suppl 1:S2. doi: 10.1186/1471-2091-9-S1-S2. Review.

15.

PPARgamma-independent antitumor effects of thiazolidinediones.

Wei S, Yang J, Lee SL, Kulp SK, Chen CS.

Cancer Lett. 2009 Apr 18;276(2):119-24. doi: 10.1016/j.canlet.2008.08.008. Epub 2008 Sep 13. Review.

16.

CXCR4 in Cancer and Its Regulation by PPARgamma.

Richard CL, Blay J.

PPAR Res. 2008;2008:769413. doi: 10.1155/2008/769413.

17.

Activation of Penile Proadipogenic Peroxisome Proliferator-Activated Receptor gamma with an Estrogen: Interaction with Estrogen Receptor Alpha during Postnatal Development.

Mansour MM, Goyal HO, Braden TD, Dennis JC, Schwartz DD, Judd RL, Bartol FF, Coleman ES, Morrison EE.

PPAR Res. 2008;2008:651419. doi: 10.1155/2008/651419.

18.

A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells.

Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, Lu PJ, Lai MD, Chen CS.

J Biol Chem. 2008 Sep 26;283(39):26759-70. doi: 10.1074/jbc.M802160200. Epub 2008 Jul 23.

19.

PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate.

Glazer RI, Yuan H, Xie Z, Yin Y.

PPAR Res. 2008;2008:247379. doi: 10.1155/2008/247379.

20.

Supplemental Content

Support Center